Stoke Therapeutics (NASDAQ: STOK) CMO exercises 10,000 units and sells shares

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. reported insider equity transactions by its Chief Medical Officer. On December 3, 2025, 10,000 performance stock units were exercised at $0, converting into 10,000 shares of common stock. Part of these shares were sold in issuer-mandated transactions to cover tax withholding tied to vesting of restricted stock units.

On December 4 and 5, 2025, the officer sold blocks of common stock in multiple trades, including 1,373 shares at a weighted average price of $30.7635, 323 shares at $31.3164, 1,673 shares at $31.3304, and 1,989 shares at $31.3453. Some sales were made under a pre-established Rule 10b5-1 trading plan. After these transactions, the officer beneficially owned 19,798 shares of Stoke Therapeutics common stock, held directly.

Insider Trade Summary

Net Seller: 5,358 shares ($167,115)

Net Sell 6 txns

Insider Ticho Barry

Role CHIEF MEDICAL OFFICER

Sold 5,358 shs ($167K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,673	$31.3304	$52K
Sale	Common Stock	1,989	$31.3453	$62K
Sale	Common Stock	1,373	$30.7635	$42K
Sale	Common Stock	323	$31.3164	$10K
Exercise	Performance Stock Units	10,000	$0.00	--
Exercise	Common Stock	10,000	$0.00	--

Holdings After Transaction: Common Stock — 21,787 shares (Direct); Performance Stock Units — 0 shares (Direct)

Footnotes (1)

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		M		10,000	A	$0	25,156	D
Common Stock	12/04/2025		S(1)		1,373	D	$30.7635(2)	23,783	D
Common Stock	12/04/2025		S(1)		323	D	$31.3164(3)	23,460	D
Common Stock	12/05/2025		S(1)		1,673	D	$31.3304(4)	21,787	D
Common Stock	12/05/2025		S(5)		1,989	D	$31.3453	19,798	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(6)	12/03/2025		M			10,000	(7)	12/03/2025	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.

5. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

6. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

7. Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Stoke Therapeutics (STOK) disclose in this filing?

The filing shows the Chief Medical Officer exercised 10,000 performance stock units at $0 on December 3, 2025, receiving 10,000 common shares, and then sold several blocks of common stock on December 4 and 5, 2025 at weighted average prices around $31 per share.

How many Stoke Therapeutics (STOK) shares does the insider own after these transactions?

Following the reported transactions, the Chief Medical Officer beneficially owned 19,798 shares of Stoke Therapeutics common stock, held directly.

What prices were the Stoke Therapeutics (STOK) shares sold for in the reported trades?

Reported sales included 1,373 shares at a weighted average of $30.7635, 323 shares at $31.3164, 1,673 shares at $31.3304, and 1,989 shares at $31.3453, with some trades executed across price ranges noted in the footnotes.

Were any of the Stoke Therapeutics (STOK) insider sales related to tax withholding?

Yes. One reported transaction is described as an issuer-mandated sale to satisfy tax withholding liabilities arising from the vesting and settlement of restricted stock units.

Did the Stoke Therapeutics (STOK) insider use a Rule 10b5-1 trading plan?

The filing states that one of the reported transactions on December 5, 2025 was executed under a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.

What are the key details of the performance stock units exercised by the Stoke Therapeutics (STOK) insider?

The derivative table shows 10,000 performance stock units with an exercise price of $0, exercisable and settled into 10,000 shares of common stock on December 3, 2025, after which no units remained beneficially owned.

How did the restricted stock units for the Stoke Therapeutics (STOK) insider vest?

The footnotes explain that each restricted stock unit represents a right to receive one share of common stock. Half of the award vested on December 3, 2024, and the remainder vested or vests on December 3, 2025, subject to continued service.